Cranberry juice is used routinely, especially among women and the elderly, to prevent and treat urinary tract infections. These individuals are likely to be taking medications concomitantly with cranberry juice, leading to concern about potential drug-dietary substance interactions, particularly in the intestine, which, along with the liver, is rich in expression of the prominent drug metabolizing enzyme, cytochrome P450 3A (CYP3A). Using a systematic in vitro-in vivo approach, a cranberry juice product was identified recently that elicited a pharmacokinetic interaction with the CYP3A probe substrate midazolam in 16 healthy volunteers. Relative to water, cranberry juice inhibited intestinal first-pass midazolam metabolism. In vitro studies were initiated to identify potential enteric CYP3A inhibitors from cranberry via a bioactivity-directed fractionation approach involving dried whole cranberry [Vaccinium macrocarpon Ait. (Ericaceae)], midazolam, and human intestinal microsomes (HIM). Three triterpenes (maslinic acid, corosolic acid, and ursolic acid) were isolated. The inhibitory potency (IC50) of maslinic acid, corosolic acid, and ursolic acid was 7.4, 8.8, and < 10 µM, respectively, using HIM as the enzyme source and 2.8, 4.3, and < 10 µM, respectively, using recombinant CYP3A4 as the enzyme source. These in vitro inhibitory potencies, which are within the range of those reported for two CYP3A inhibitory components in grapefruit juice, suggest that these triterpenes may have contributed to the midazolam-cranberry juice interaction observed in the clinical study.
1
Huang S M, Strong J M, Zhang L, Reynolds K S, Nallani S, Temple R, Abraham S, Habet S A, Baweja R K, Burckart G J, Chung S, Colangelo P, Frucht D, Green M D, Hepp P, Karnaukhova E, Ko H S, Lee J I, Marroum P J, Norden J M, Qiu W, Rahman A, Sobel S, Stifano T, Thummel K, Wei X X, Yasuda S, Zheng J H, Zhao H, Lesko L J.
New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process.
J Clin Pharmacol.
2008;
48
662-670
2
Paine M F, Oberlies N H.
Clinical relevance of the small intestine as an organ of drug elimination: drug-fruit juice interactions.
Expert Opin Drug Metab Toxicol.
2007;
3
67-80
3
Lown K S, Bailey D G, Fontana R J, Janardan S K, Adair C H, Fortlage L A, Brown M B, Guo W, Watkins P B.
Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression.
J Clin Invest.
1997;
99
2545-2553
4
Mertens-Talcott S U, Zadezensky I, De Castro W V, Derendorf H, Butterweck V.
Grapefruit-drug interactions: can interactions with drugs be avoided?.
J Clin Pharmacol.
2006;
46
1390-1416
5
Paine M F, Widmer W W, Hart H L, Pusek S N, Beavers K L, Criss A B, Brown S S, Thomas B F, Watkins P B.
A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction.
Am J Clin Nutr.
2006;
83
1097-1105
6
Gardiner P, Graham R, Legedza A T R, Ahn A C, Eisenberg D M, Phillips R S.
Factors associated with herbal therapy use by adults in the United States.
Altern Ther Health Med.
2007;
13
22-29
7
Gardiner P, Graham R E, Legedza A T R, Eisenberg D M, Phillips R S.
Factors associated with dietary supplement use among prescription medication users.
Arch Intern Med.
2006;
166
1968-1974
8
Ngo N, Yan Z, Graf T N, Carrizosa D R, Kashuba A D, Dees E C, Oberlies N H, Paine M F.
Identification of a cranberry juice product that inhibits enteric CYP3A-mediated first-pass metabolism in humans.
Drug Metab Dispos.
2009;
37
514-522
9
Foo L Y, Lu Y R, Howell A B, Vorsa N.
A-type proanthocyanidin trimers from cranberry that inhibit adherence of uropathogenic P-fimbriated Escherichia coli.
J Nat Prod.
2000;
63
1225-1228
15
Grenier J, Fradette C, Morelli G, Merritt G J, Vranderick M, Ducharme M P.
Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans.
Clin Pharmacol Ther.
2006;
79
255-262
16
Lilja J J, Backman J T, Neuvonen P J.
Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine, and midazolam–probes of CYP2C9, CYP1A2, and CYP3A4.
Clin Pharmacol Ther.
2007;
81
833-839
18
Paine M F, Hart H L, Ludington S S, Haining R L, Rettie A E, Zeldin D C.
The human intestinal cytochrome P450 “pie”.
Drug Metab Dispos.
2006;
34
880-886
19
Graf T N, Wani M C, Agarwal R, Kroll D J, Oberlies N H.
Gram-scale purification of flavonolignan diastereoisomers from Silybum marianum (milk thistle) extract in support of preclinical in vivo studies for prostate cancer chemoprevention.
Planta Med.
2007;
73
1495-1501
20
Alves J S, de Castro J C M, Freire M O, da-Cunha E V L, Barbosa J M, de Silva M S.
Complete assignment of the 1H and 13C NMR spectra of four triterpenes of the ursane, artane, lupane and friedelane groups.
Magn Reson Chem.
2000;
38
201-206
21
Zucaro Y L, Compagnone R S, Hess S C, Delle Monache F.
6 beta-hydroxymaslinic acid, a triterpene from Vochysia ferruginea.
J Braz Chem Soc.
2000;
11
241-244
22
Bilia A R, Palme E, Catalano S, Flamini G, Morelli I.
New triterpenoid saponins from the roots of Potentilla tormentilla.
J Nat Prod.
1994;
57
333-338
23
Seo S, Tomita Y, Tori K.
13C NMR spectra of urs-12-enes and application to structural assignments of components of Isodon japonicus Hara tissue cultures.
Tetrahedron Lett.
1975;
7-10
24
Wang M Z, Wu J Q, Bridges A S, Zeldin D C, Kornbluth S, Tidwell R R, Hall J E, Paine M F.
Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.
Drug Metab Dispos.
2007;
35
2067-2075
25
Bennett B C, Balick M J.
Phytomedicine 101: plant taxonomy for preclinical and clinical medicinal plant researchers.
J Soc Integr Oncol.
2008;
6
150-157
26
Greenblatt D J, von Moltke L L, Harmatz J S, Chen G, Weemhoff J L, Jen C, Kelley C J, LeDuc B W, Zinny M A.
Time course of recovery of cytochrome p450 3A function after single doses of grapefruit juice.
Clin Pharmacol Ther.
2003;
74
121-129
27
Paine M F, Criss A B, Watkins P B.
Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties.
Drug Metab Dispos.
2004;
32
1146-1153
28
Paine M F, Criss A B, Watkins P B.
Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition.
J Pharmacol Exp Ther.
2005;
312
1151-1160
